Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-16: Belantamab Mafodotin + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT07614360Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2026
- Primary completion
- Feb 2029
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07614360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614360.